# GLOW peptide: GHK-Cu, BPC-157 and TB-500, read from the record > GLOW peptide is a research blend of three peptides — GHK-Cu, BPC-157 and TB-500. What each constituent does in the literature, why they are combined, and what the blend has not been tested for. Three peptides, three distinct mechanisms, one combined formulation that has never been tested as a unit in a controlled human trial. The constituent evidence is set out below, marked for what it shows and where it stops. ## What GLOW peptide is GLOW peptide is not a single molecule. It is a co-formulated research blend of three distinct peptides — GHK-Cu, BPC-157 and TB-500 — combined for complementary mechanisms rather than tested as one drug. Across consumer and clinic sources the GLOW name resolves consistently to that trio: GHK-Cu, the copper(II) chelate of the tripeptide glycyl-L-histidyl-L-lysine; BPC-157, a synthetic 15-amino-acid pentadecapeptide; and TB-500, the acetylated heptapeptide fragment Ac-LKKTETQ derived from thymosin beta-4. This site reads the record. Each constituent carries its own published literature — much of it preclinical, some of it small human work — and the case for combining them is mechanistic, not empirical. There are no controlled clinical trials of the GLOW blend itself for any indication [9]. A 2026 Sports Medicine review that names all three constituents together concluded that such unapproved peptides show favorable tissue-repair outcomes in animal models but that rigorous human safety data are scarce, with potential for serious harm [9]. GLOW is a supplier- and clinic-formulated combination, not a regulated drug product and not a single chemical entity. Ratios and purity vary by source. What follows is the constituent evidence, the combination rationale, [dosing in the research literature](/dosage), and [GLOW legal status and 503A category](/legal-status) — each claim tied to its study. ## GLOW Peptides: The Three-Peptide Combination GLOW peptides cover three different stages of tissue repair, which is the rationale clinics give for the blend. GHK-Cu is the matrix-building signal: it stimulates dermal fibroblast synthesis of collagen, elastin and glycosaminoglycans and rebalances metalloproteinases [1][2]. BPC-157 is the vascular and cytoprotective signal: it up-regulates VEGFR2 and the VEGFR2-Akt-eNOS pathway and accelerates connective-tissue healing in animal models [3][4]. TB-500 is the cell-mobility and anti-scarring signal: as a fragment of thymosin beta-4 it sequesters monomeric actin and promotes cell migration and reduced scarring [5][7]. A commonly cited research-label ratio is 10 mg BPC-157 / 10 mg TB-500 / 50 mg GHK-Cu per vial. That is a supplier labeling convention, not a clinically validated dose. The blend has never been dosed in a controlled human trial [9]. Read each constituent's evidence on the [tissue-repair and wound-healing research](/recovery-research) page and the mechanism detail under [how the three-peptide blend works](/research). ## Why GHK-Cu, BPC-157 and TB-500 Are Combined in One Blend The glow blend pairs three peptides whose mechanisms are distinct but converge on tissue repair and skin renewal. The thesis is complementary coverage: a matrix-building signal (GHK-Cu), a vascular and cytoprotective signal (BPC-157), and a cell-mobility and anti-scarring signal (TB-500), so the trio addresses more of the repair cascade than any single peptide. The synergy is a mechanistic rationale — no study has tested the three-peptide blend head-to-head against its parts in humans [9]. The combination also raises questions the literature has not answered. Combination pharmacokinetics, drug-interaction effects, and the stability of co-formulating a copper complex with two other peptides are unstudied; copper redox chemistry and solution pH create theoretical compatibility concerns specific to GLOW. The honest reading: a plausible rationale, an untested formulation. ## How GLOW Compares to the KLOW and Wolverine Stacks A glow peptide stack is one of three closely related research combinations, and the names are easy to confuse. GLOW is GHK-Cu + BPC-157 + TB-500. The distinct KLOW blend adds a fourth peptide, KPV, to that same trio. The Wolverine blend is narrower — BPC-157 + TB-500 only, with no GHK-Cu and therefore none of the copper-tripeptide skin rationale. None of the three is a single approved drug. Each is a non-standardized research combination whose evidence base is the literature on its individual constituents plus a mechanistic argument for combining them. The distinguishing variable across the three is simply which peptides are present; the underlying constituent evidence is shared. --- The GLOW peptide record, set in plain type — three constituent literatures read for what they show and where they stop, prescribed by no clinic and sold by no one.